Tasly: Net profit expected to increase by 19.81% year-on-year in 2025, with a record high number of new products released

On March 20, Tasly Biotech released its 2025 annual report. The announcement shows that 2025 marks the company’s 30th anniversary. The company is focused on “improving operational quality” as its core goal, continuously deepening its scientific nutrition strategy. During the reporting period, the company achieved operating revenue of 6.265 billion yuan, of which overseas business LSG generated 934 million yuan, a year-on-year increase of 17.73%. The net profit attributable to shareholders of the listed company was 782 million yuan, up 19.81% year-on-year. Net cash flow from operating activities reached 1.214 billion yuan, an increase of 76.94%.

According to the announcement, 2025 is defined by the company as the “first big year for new product launches in history,” with a record high number of new products introduced throughout the year. Relying on self-developed patented technologies such as “Vimineral Layering,” the company launched a series of differentiated new products with competitive advantages.

The company made breakthroughs in pharmaceuticals and medical foods, launching its first self-developed OTC (over-the-counter) product, “Jianliduo Sulfate Amino Glucosamine Capsules,” and the first specialized medical full-nutrition formula powder, “Meiyile,” further expanding its product boundaries. During the reporting period, sales of new products, including multi-layer tablets, accounted for nearly 20%, optimizing the company’s product strategy and brand assets.

R&D investment during the period was 88.9542 million yuan. The company published 27 scientific research papers, added 15 domestic invention patents and 2 overseas patents, and obtained 7 health food registration certificates and 30 filing certificates. The company continues to promote the “scientific nutrition” strategy, focusing on the research and development of proprietary patented raw materials and formulas. By the end of the reporting period, the company held 462 domestic patents, including 145 invention patents related to raw materials and formulas, and 18 overseas patents.

Tasly Biotech stated in the announcement that in the face of challenges, the company has chosen a “re-entrepreneurship” mindset, focusing on growth, deploying multiple channels across all business segments, and making major innovations in key categories with significant potential for commercialization, such as high-functionality, new functions, and new dosage forms. The company aims to ensure brand investment and accelerate global market expansion. It is also advancing the deep integration of AI technology with all business scenarios to drive innovation and efficiency improvements. (Wang Luo)

【Source: China Securities Journal · China Securities Network】